Status:
COMPLETED
Hypofractionated Radiotherapy for Prostate Cancer
Lead Sponsor:
Consorci Sanitari de Terrassa
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
Radiotherapy is a standard definitive treatment for men with localized prostate cancer. Recent improvements in technology allow high doses of radiation to be delivered to the prostate in less days wi...
Detailed Description
Recent evidence suggests that the same or better outcomes might be achieved in prostate cancer by ussing a higher dose of radiation per fraction ( 3Gy) with the consequent decrease in total days Quali...
Eligibility Criteria
Inclusion
- Histologic confirmation of adenocarcinoma of the prostate by biopsy
- Performance Status 0-2
- Signed informed consent form
Exclusion
- Positive lymph-nodes or metastatic disease from prostate cancer on imaging studies
- Anticoagulant treatment, individual assessment of antiplatelet therapy
- Previous pelvic radiotherapy
- Previous surgery for prostate cancer
- Previous transurethral resection of the prostate
- History of Crohn's Disease or Ulcerative Colitis
- Antecedents of rectal fistulas in the last 10 years
- Previous significant urinary obstructive symptoms
- Previous chemotherapeutic treatments
- Non-compliance with constraints established in this protocol (see special section
Key Trial Info
Start Date :
October 5 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 5 2021
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT03851926
Start Date
October 5 2016
End Date
October 5 2021
Last Update
February 10 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital de Terrassa
Terrassa, Barcelona, Spain, 08227